Navigation Links
FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults
Date:6/27/2008

CONCERTA(R) now available for patients with ADHD ages 6 to 65

RARITAN, N.J., June 27 /PRNewswire/ -- ADHD is the most common emotional, cognitive and behavioral disorder treated in children(1), and according to the National Institute of Mental Health (NIMH), between 30 percent and 70 percent of children with ADHD continue to exhibit symptoms in the adult years(2). ADHD is thought to affect about eight million, or one in 20, adults in the United States(3), and research on the life span of the condition notes the disorder impairs academic, social and occupational functioning(1), and is associated with academic underachievement, conduct problems, underemployment, motor vehicle safety and difficulties with personal relationships(1).

Today, there's a new treatment option for the millions of adults in the United States with ADHD: Johnson & Johnson Pharmaceutical Research & Development L.L.C. (J&JPRD) announced the U.S. Food and Drug Administration (FDA) approved J&JPRD's Supplemental New Drug Application (sNDA) for CONCERTA(R) treatment of ADHD in adults ages 18 to 65. The doses approved for adults range from 18 to 72 mg daily.

Today's approval expands the CONCERTA(R) indication from children and adolescents into adults with ADHD, and offers these patients a patented once- daily formulation. Using its unique OROS(R) delivery system, the CONCERTA(R) formulation delivers an initial dose of medication when the tablet is ingested. Medication is then delivered into the bloodstream at a controlled rate throughout the day.

The CONCERTA(R) brand, which was the first 12-hour extended-release methylphenidate (MPH) treatment for ADHD, is the market leader for MPH treatment of children and adolescents with ADHD. CONCERTA(R) is marketed in the United States by McNeil Pediatrics(TM), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

"What we've seen in the growing body of knowledge on adult ADHD suggests a challenging burden of impairme
'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & DevelopmentL.L.C.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
2. Big Win for Biodiesel: ASTM Approves New Biodiesel Blend Specifications
3. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
4. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
5. FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceuticals TRELSTAR(R) DEPOT and TRELSTAR(R) LA
6. FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
7. Maryland Approves Medicaid Reimbursement for ActiPatch(R)
8. Healthcare Coalition Approves Tools to Improve Patient Safety During Transitions of Care
9. Medicare Approves in Home Sleep Apnea Testing
10. 3SBio Inc. Approves Share Repurchase Program
11. Baxters Board of Directors Approves New Share Repurchase Authorization of $2 Billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014 ... zur Erfassung biologischer Daten in Verbindung mit ... patentiert. Das LBS nimmt gleichzeitig mehrere Blutproben ... Patienten und sucht erhöhte biologische Aktivitäten in ... die Entdeckung und Entwicklung neuer Medikamente und ...
(Date:7/28/2014)... The Workgroup for Electronic Data Interchange (WEDI), the ... IT to create efficiencies in healthcare information exchange, announced ... has developed an issue brief titled, “What is the ... Workgroup, a part of WEDI’s Strategic National HPID Implementation ... Medicaid Services (CMS) to identify common misuse of the ...
(Date:7/28/2014)... CA and Annapolis Junction, MD (PRWEB) July 28, 2014 ... and research leader in personalized medicine, will be exhibiting ... services at this year’s International Spine Intervention Society’s ... take place July 30th-August 3rd, at the Hyatt Regency, ... designed to enhance the knowledge and clinical competence of ...
(Date:7/28/2014)... July 28, 2014 ... Identification Market by Products (Consumables, Instruments, Services), Methods (Phenotypic, ... User (Detection, Characterization) - Global Forecasts to ... Market is estimated at $896.5 Million in ... Million by 2019, growing at a CAGR ...
Breaking Biology Technology:PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 2PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 3PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 4WEDI’s HPID Workgroup Announces Release of Issue Brief: “What is the Difference Between a Health Plan and Payer?” 2Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting 2Microbial Identification Market worth $1,194.1 Million by 2019 2Microbial Identification Market worth $1,194.1 Million by 2019 3
... introduces a,new accessory, MPX(TM) (Multiplex) Blotting System, for ... can be incorporated into a,variety of assays including ... transduction pathway analysis, or any,other common Western blotting ... 7 x 8.5 cm., Processing is as ...
... Cardium Therapeutics,(Amex: CXM ) and ... that,InnerCool has entered into a exclusive commercialization ... distributor of medical products.,N.G.C. Medical primarily sells ... interventional cardiology markets. They also provide,in-service management ...
... REDWOOD CITY, Calif., June 19 Cardica, Inc.,(Nasdaq: ... Ph.D., the,company,s president and chief executive officer, is scheduled ... Thursday, June 26, 2008,at 12:30 p.m. Eastern Time. The ... To access the live and subsequently archived webcast ...
Cached Biology Technology:LI-COR(R) Biosciences Introduces New Tools for High Throughput Western Blotting 2Cardium's InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems 2Cardium's InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems 3Cardium's InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems 4Cardium's InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems 5Cardium's InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems 6
(Date:7/28/2014)... He calls himself the bug hunter, but the target ... be found and identified with special methods and instruments. ... State Veterinary Diagnostic Laboratory at Kansas State University, recently ... enterovirus G, which is an important find in the ... cells, but didn,t know what it was," Hause said. ...
(Date:7/28/2014)... (July 28, 2014)The Brain & Behavior Research Foundation ... and Freedman Prizes, recognizing exceptional clinical and basic ... by NARSAD Young Investigator Grants. The grants enable ... neurobiological and psychosocial research for the prevention, early ... affect one in four people. , Six young ...
(Date:7/28/2014)... and treat HIV infection has been problematic until now ... arouse as they get rid of the invaders. Now, ... and the National Institutes of Health (NIH) have demonstrated ... around the time of infection could have long-term ... appeared in Nature . , Interferons, named ...
Breaking Biology News(10 mins):Researcher using next-generation sequencing to rapidly identify pathogens 2Researcher using next-generation sequencing to rapidly identify pathogens 3The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 2The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 3The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 4Interfering with interferon 2
... common type of lung cancer are notoriously insensitive to ... cellular pathways that regulate responses to cisplatin have now ... the journal Cell Reports . The findings reveal ... how these patients will respond to chemotherapy, as well ...
... July 26, 2012 Administering high-doses of interleukin-2 (IL-2) has ... metastatic melanoma. An article published in the current ... peer-reviewed journal from Mary Ann Liebert, Inc. ( http://www.liebertpub.com ... the most effective. The article is available free ...
... July 26, 2012 Congenital hypothyroidism is thyroid hormone ... to neurocognitive impairments in infants and children. Although ... daily during pregnancy for normal fetal thyroid hormone production ... 1,100 g to be the safe upper limit for ...
Cached Biology News:New biomarker for common lung cancer predicts responses to chemotherapy 2Study associates excess maternal iodine supplementation with congenital hypothyroidism in newborns 2